Medopad

Fiercepharma | May 06, 2020

Gilead Sciences can only produce so much of its newly authorized COVID-19 drug remdesivir, so it’s scouting other companies to bolster global supply. Even as it presses ahead with its own remdesivir ramp-up, Gilead says it’s in licensing talks with the “world’s leading chemical and pharmaceutical manufacturing companies” about their ability to produce remdesivir for countries in Europe, Asia and beyond until at least 2022. Remdesivir manufacturing relies on “s...

Capsa Healthcare | August 14, 2020

Capsa Healthcare ("Capsa"), a portfolio company of Levine Leichtman Capital Partners ("LLCP"), announced today that it has acquired NewRobo Development B.V. and subsidiaries (collectively, "RoboPharma"). RoboPharma, based in Waalwijk, Netherlands, creates and implements pharmacy automation solutions for some of the largest pharmacies in Europe. Capsa is a leading provider of innovative, highly engineered workflow products that increase efficiency and reduce costs, e...

Pharma Tech

SciNeuro Pharmaceuticals | October 26, 2021

SciNeuro Pharmaceuticals a leader in the discovery and development of innovative therapeutics for the treatment of neurological diseases, and Mabylon AG, a leader in the discovery and characterization of human-derived antibodies against therapeutic targets, today announced the establishment of a multi-program collaboration and license agreement. Under the collaboration, MabSciNeuro and Mabylon will collaborate on multiple targets that encompass serious neurological diseases including TAR DNA bin...

Pharma Tech

COUR Pharmaceuticals | January 11, 2022

COUR Pharmaceuticals, a biotechnology company developing novel immune-modifying nanoparticles to treat immune disorders, today announced the U.S. Food and Drug Administration granted Fast Track Designation to the Company's investigational therapy CNP-104 for the treatment of Primary Biliary Cholangitis. CNP-104 aims to reprogram the immune system to address autoimmune causes of PBC. "We are pleased to have received Fast Track Designation for CN...